Fig. 4

Protein level of EMT markers in LX-2 treated with TGF-β, IL-1β and Canakinumab. Protein expression of a FN, b VIM and c α-SMA in LX-2 treated with TGF-β (10 ng/ml), IL-1β (10 ng/ml) with and without Canakinumab (5 μg/ml). Upper part: representative western blotting of all the experiments. Lower part: histograms showing mean ± SD of protein expression levels normalized to GAPDH. **p < 0.01 vs control cells (CTR); ^°°p < 0.01 vs TGF-β; ^##p < 0.01 vs IL-1β. d Representative immunofluorescence images from three independent experiments for phalloidin, VIM and α-SMA in LX-2 cells treated with IL-1β or TGF-β in presence and absence of Canakinumab (Zoom × 400)